GSE98888 Underestimation of inadvertent morpholino RNA targets: evidence from the study of Danio rerio Ser/Arg-rich splicing factors using gene editing tools
Contributors : Marine Joris ; Patrick Motte ; Marc MullerSeries Type : Expression profiling by high throughput sequencingOrganism : Danio rerioWe used morpholinos and gene editing tools to inactivate the srsf5a gene. In contrast to srsf5a homozygous mutants that did not display any phenotypic traits, microinjection of sMOsrsf5a led to developmental defects. By using RNA sequencing on morphants and control embryos we were able to identify a plethora of morpholino inadvertant target.
Authors: Fischetti A, Romano N, Mussetto I, Merlo G, Burlando M, Cozzani E, Muda A, Garlaschi G, Parodi A PMID: 30229643 [PubMed - as supplied by publisher]
Authors: Brambilla L, Minuti A, Brambilla M, Tourlaki A, Genovese G, Berti E PMID: 30229642 [PubMed - as supplied by publisher]
Authors: Veraldi S, Moltrasio C, Spinelli F, Nazzaro G PMID: 30229641 [PubMed - as supplied by publisher]
Authors: Radi G, Campanati A, Diotallevi F, Molinelli E, Offidani A Abstract BACKGROUND: Apremilast is a "small molecule", an oral phosphodiesterase 4 inhibitor indicated for the twice- daily treatment of adults with psoriasis (PsO) and psoriatic arthritis (PsA). Data concerning clinical experience in real world setting with Apremilast for psoriasis are still exiguous, and aim of this report is to provide our experience in the use of Apremilast in out-patient setting. METHODS: Ten caucasian individuals (6 male, 4 females; mean age 69,3; range 53-81 years) affected by moderate to severe plaque psoriasi...
Authors: Di Prete M, Ferlosio A, Mazzilli S, Bianchi L, Orlandi A, Campione E PMID: 30229639 [PubMed - as supplied by publisher]
Authors: Rossi A, Garelli V, Muscianese M, Pranteda G, Caro G, D'arino A, Fortuna MC PMID: 30229638 [PubMed - as supplied by publisher]
Authors: Gualtieri B, Panduri S, Chiricozzi A, Romanelli M PMID: 30229637 [PubMed - as supplied by publisher]
CONCLUSIONS: This study demonstrated the increased risk of skin cancer in transplant patients during the first 7 years of follow-up and made the dermatologists aware about the need of a regular cutaneous follow up for this subset of patients. PMID: 30229636 [PubMed - as supplied by publisher]
Authors: Caposiena Caro RD, Coppola A, Didona D PMID: 30229635 [PubMed - as supplied by publisher]
CONCLUSIONS: This study suggests that topical EGF is a safe, noninvasive, and effective treatment for melasma. J Drugs Dermatol. 2018;17(6):970-973. PMID: 30235384 [PubMed - in process]